{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:43:50Z","timestamp":1793313830007,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019220","name":"Salahaddin University-Erbil","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002668","name":"Bolu Abant \u0130zzet Baysal University","doi-asserted-by":"publisher","award":["2021.03.03.1520"],"award-info":[{"award-number":["2021.03.03.1520"]}],"id":[{"id":"10.13039\/501100002668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmc.2025.118409","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T08:07:11Z","timestamp":1758701231000},"page":"118409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Synthesis, in vitro and in silico anticancer evaluations of novel styryl 1,3,4-oxadiazole-sulfonamide hybrids for colorectal cancer"],"prefix":"10.1016","volume":"131","author":[{"given":"Hawkar I.","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur Can","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuad O.","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammet","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baram A.","family":"Hamah Ameen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.bmc.2025.118409_bb0005","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1021\/jf0201677","article-title":"Synthesis, fungicidal activity, and 3D-QSAR of pyridazinone-substituted 1, 3, 4-oxadiazoles and 1, 3, 4-thiadiazoles","volume":"50","author":"Zou","year":"2002","journal-title":"J Agric Food Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118409_bb0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejmech.2006.10.003","article-title":"Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-(1-adamantyl)-5-substituted-1, 3, 4-oxadiazoles and 2-(1-adamantylamino)-5-substituted-1, 3, 4-thiadiazoles","volume":"42","author":"Kadi","year":"2007","journal-title":"Eur J Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2025.118409_bb0015","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1016\/j.ejmech.2010.06.023","article-title":"Hypervalent iodine (III) mediated synthesis of novel unsymmetrical 2, 5-disubstituted 1, 3, 4-oxadiazoles as antibacterial and antifungal agents","volume":"45","author":"Prakash","year":"2010","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2025.118409_bb0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0014-827X(01)01176-4","article-title":"Synthesis and anti-inflammatory activity of 1-acylthiosemicarbazides, 1, 3, 4-oxadiazoles, 1, 3, 4-thiadiazoles and 1, 2, 4-triazole-3-thiones","volume":"57","author":"Palaska","year":"2002","journal-title":"Il Farmaco"},{"key":"10.1016\/j.bmc.2025.118409_bb0025","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejmech.2013.02.040","article-title":"Synthesis and evaluation of 2, 5-di (4-aryloylaryloxymethyl)-1, 3, 4-oxadiazoles as anti-cancer agents","volume":"63","author":"Gurupadaswamy","year":"2013","journal-title":"Eur J Med Chem"},{"issue":"6","key":"10.1016\/j.bmc.2025.118409_bb0030","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.bmcl.2009.01.089","article-title":"1, 3, 4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position","volume":"19","author":"Johns","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"13","key":"10.1016\/j.bmc.2025.118409_bb0035","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2174\/138955711797655407","article-title":"1, 3, 4-Oxadiazole: a privileged structure in antiviral agents","volume":"11","author":"Li","year":"2011","journal-title":"Mini Reviews in Medicinal Chemistry"},{"issue":"18","key":"10.1016\/j.bmc.2025.118409_bb0040","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1021\/jm800245z","article-title":"Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection","volume":"51","author":"Summa","year":"2008","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmc.2025.118409_bb0045","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s11030-022-10548-9","article-title":"Synthesis of new 3-acetyl-1, 3, 4-oxadiazolines combined with pyrimidines as antileishmanial and antiviral agents","volume":"27","author":"Lachhab","year":"2023","journal-title":"Molecular Diversity"},{"issue":"15","key":"10.1016\/j.bmc.2025.118409_bb0050","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.3390\/molecules25153315","article-title":"Synthesis of new planar-chiral linked [2,2] paracyclophanes-N-([2,2]-paracyclophanylcarbamoyl)-4-[2,2] paracyclophanylcarboxamide [2,2] paracyclophanyl-substituted triazolthiones and-substituted oxadiazoles","volume":"25","author":"Aly","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bmc.2025.118409_bb0055","first-page":"35","article-title":"Antibacterial activity of Furamizole on mycoplasma gallisepticum","volume":"13","author":"Seo","year":"1973","journal-title":"Korean Journal of Veterinary Research"},{"issue":"16","key":"10.1016\/j.bmc.2025.118409_bb0060","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bmcl.2019.06.041","article-title":"Sulfonamide derivatives as multi-target agents for complex diseases","volume":"29","author":"Apayd\u0131n","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"issue":"21","key":"10.1016\/j.bmc.2025.118409_bb0065","doi-asserted-by":"crossref","first-page":"9618","DOI":"10.1021\/acs.jmedchem.9b01032","article-title":"Identification of CNS-penetrant aryl sulfonamides as isoform-selective NaV1. 6 inhibitors with efficacy in mouse models of epilepsy","volume":"62","author":"Focken","year":"2019","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2025.118409_bb0070","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.bmcl.2014.12.006","article-title":"Sulfonamides as multifunctional agents for Alzheimer\u2019s disease","volume":"25","author":"Bag","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118409_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113837","article-title":"Sulfonamide derivatives as potential anti-cancer agents and their SARs elucidation","volume":"226","author":"Wan","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118409_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bioorg.2016.12.007","article-title":"Synthesis, characterization, in vitro cytotoxicity and antimicrobial investigation and evaluation of physicochemical properties of novel 4-(2-methylacetamide) benzenesulfonamide derivatives","volume":"70","author":"Durgun","year":"2017","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118409_bb0085","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ejmech.2016.08.060","article-title":"Biological evaluation of some new N-(2, 6-dimethoxypyrimidinyl) thioureido benzenesulfonamide derivatives as potential antimicrobial and anticancer agents","volume":"124","author":"Ghorab","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118409_bb0090","article-title":"Unveiling anti-diabetic potential of new thiazole-sulfonamide derivatives: design, synthesis, in vitro bio-evaluation targeting DPP-4, \u03b1-glucosidase, and \u03b1-amylase with in-silico ADMET and docking simulation","volume":"151","author":"Thabet","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118409_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103852","article-title":"Iqbal, J, exploiting oxadiazole-sulfonamide hybrids as new structural leads to combat diabetic complications via aldose reductase inhibition","volume":"99","author":"Javid","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118409_bb0100","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.bioorg.2017.10.005","article-title":"T, heterocyclic periphery in the design of carbonic anhydrase inhibitors: 1,2,4-Oxadiazol-5-yl benzenesulfonamides as potent and selective inhibitors of cytosolic hCA II and membrane-bound hCA IX isoforms","volume":"76","author":"Krasavin","year":"2018","journal-title":"Bioorg Chem"},{"issue":"3","key":"10.1016\/j.bmc.2025.118409_bb0105","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jsps.2016.07.004","article-title":"Synthesis, characterization and biological evaluation of novel 2,5 substituted-1,3,4-oxadiazole derivatives","volume":"25","author":"Kavitha","year":"2017","journal-title":"Saudi Pharmaceutical Journal"},{"key":"10.1016\/j.bmc.2025.118409_bb0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejmech.2014.11.011","article-title":"Synthesis and in vitro antiproliferative activity of new 1,3,4-oxadiazole derivatives possessing sulfonamide moiety","volume":"90","author":"El-Din","year":"2015","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118409_bb0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/ijms18010197","article-title":"Colorectal carcinoma: a general overview and future perspectives in colorectal cancer","volume":"18","author":"M\u00e1rmol","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bmc.2025.118409_bb0120","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/1389557521666210226145837","article-title":"1, 3, 4-Oxadiazole containing compounds as therapeutic targets for cancer therapy","volume":"22","author":"Ahsan","year":"2022","journal-title":"Mini Reviews in Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2025.118409_bb0125","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3390\/biomedicines9050579","article-title":"Identifying novel actionable targets in Colon Cancer","volume":"9","author":"Cerrito","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.bmc.2025.118409_bb0130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41392-020-0116-z","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2025.118409_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102218","article-title":"Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone","volume":"98","author":"Glimelius","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.bmc.2025.118409_bb0140","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1158\/1078-0432.CCR-07-1354","article-title":"US Food and Drug Administration approval: Panitumumab for epidermal growth factor receptor\u2013expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens","volume":"14","author":"Giusti","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bmc.2025.118409_bb0145","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","article-title":"FDA drug approval summary: Panitumumab (Vectibix\u2122)","volume":"12","author":"Giusti","year":"2007","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.bmc.2025.118409_bb0150","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab\u2013FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118409_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.10.009","article-title":"Therapeutic targets in the Wnt signaling pathway: feasibility of targeting TNIK in colorectal cancer","volume":"156","author":"Masuda","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"21","key":"10.1016\/j.bmc.2025.118409_bb0160","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1038\/emboj.2009.285","article-title":"The kinase TNIK is an essential activator of Wnt target genes","volume":"28","author":"Mahmoudi","year":"2009","journal-title":"EMBO J"},{"issue":"34","key":"10.1016\/j.bmc.2025.118409_bb0165","doi-asserted-by":"crossref","first-page":"26289","DOI":"10.1074\/jbc.M109.090597","article-title":"Traf2-and Nck-interacting kinase is essential for canonical Wnt signaling in Xenopus axis formation","volume":"285","author":"Satow","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2025.118409_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13577-011-0023-2","article-title":"The enormous influence of TNIK knockdown on intracellular signals and cell survival","volume":"24","author":"Gui","year":"2011","journal-title":"Hum Cell"},{"key":"10.1016\/j.bmc.2025.118409_bb0175","doi-asserted-by":"crossref","first-page":"33534","DOI":"10.1038\/srep33534","article-title":"Comprehensive modeling and discovery of mebendazole as a novel TRAF2-and NCK-interacting kinase inhibitor","volume":"6","author":"Tan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118409_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1783-y","article-title":"Prognostic significance of Traf2-and Nck-interacting kinase (TNIK) in colorectal cancer","volume":"15","author":"Takahashi","year":"2015","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.bmc.2025.118409_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110180","article-title":"A novel aminothiazole KY-05009 with potential to inhibit Traf2-and Nck-interacting kinase (TNIK) attenuates TGF-\u03b21-mediated epithelial-to-mesenchymal transition in human lung adenocarcinoma A549 cells","volume":"9","author":"Kim","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bmc.2025.118409_bb0190","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.bmcl.2012.11.013","article-title":"Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors","volume":"23","author":"Ho","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmc.2025.118409_bb0195","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmc.2025.118409_bb0200","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1007\/s00044-013-0786-y","article-title":"Synthesis, biological evaluation, and molecular modeling of (E)-2-aryl-5-styryl-1,3,4-oxadiazole derivatives as acetylcholine esterase inhibitors","volume":"23","author":"Kamal","year":"2014","journal-title":"Med Chem Res"},{"issue":"12","key":"10.1016\/j.bmc.2025.118409_bb0205","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.3109\/13880209.2015.1005752","article-title":"Antiproliferative and apoptotic activities of extracts of Asclepias subulata","volume":"53","author":"Rascon Valenzuela","year":"2015","journal-title":"Pharm Biol"},{"issue":"1","key":"10.1016\/j.bmc.2025.118409_bb0210","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1021\/acs.jmedchem.7b01086","article-title":"The magic of crystal structure-based inhibitor optimization: development of a butyrylcholinesterase inhibitor with picomolar affinity and in vivo activity","volume":"61","author":"Kosak","year":"2018","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2025.118409_bb0215","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.3390\/app11125702","article-title":"Recent updates on the synthesis of bioactive quinoxaline-containing sulfonamides","volume":"11","author":"Irfan","year":"2021","journal-title":"Appl Sci"},{"key":"10.1016\/j.bmc.2025.118409_bb0220","series-title":"Synthesis of New Thiazolopyrimidine, Thiazolo (Imidazolo) Pyridinone Derivatives Via Multicomponent Reactions","author":"\u00c7elikel","year":"2015"},{"issue":"14","key":"10.1016\/j.bmc.2025.118409_bb0225","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1158\/1078-0432.CCR-13-2181","article-title":"Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK\/ERK pathway activation and can be overcome by combined MEK\/EGFR inhibition","volume":"20","author":"Troiani","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.bmc.2025.118409_bb0230","doi-asserted-by":"crossref","first-page":"11678","DOI":"10.1038\/s41598-017-11688-x","article-title":"Inhibition of Wnt\/\u03b2-catenin pathway and histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer","volume":"7","author":"Proto","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118409_bb0235","unstructured":"Riss TL, Moravec RA, Niles AL, et al. Cell Viability Assays. 2013 May 1 [Updated 2016 Jul 1]. In: Markossian S, Grossman A, Baskir H, et al., editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-\u200b."},{"issue":"1","key":"10.1016\/j.bmc.2025.118409_bb0240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/biom10010138","article-title":"A review of the structure\u2014activity relationship of natural and synthetic antimetastatic compounds","volume":"10","author":"Liew","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2025.118409_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104873","article-title":"Design, synthesis, modelling studies and biological evaluation of 1,3,4-oxadiazole derivatives as potent anticancer agents targeting thymidine phosphorylase enzyme","volume":"111","author":"Bajaj","year":"2021","journal-title":"Bioorg Chem"},{"issue":"5","key":"10.1016\/j.bmc.2025.118409_bb0250","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6026\/97320630016387","article-title":"Molecular docking analysis of the TNIK receptor protein with a potential inhibitor from the NPACT databas","volume":"16","author":"Rosita","year":"2020","journal-title":"Bioinformation"},{"key":"10.1016\/j.bmc.2025.118409_bb0255","author":"Abraham"},{"key":"10.1016\/j.bmc.2025.118409_bb0260","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci Rep"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625003505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:31:15Z","timestamp":1780403475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625003505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"alternative-id":["S0968089625003505"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118409","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, in vitro and in silico anticancer evaluations of novel styryl 1,3,4-oxadiazole-sulfonamide hybrids for colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118409"}}